191 related articles for article (PubMed ID: 35416319)
1. Peripheral B-cell dysregulation is associated with relapse after long-term quiescence in patients with multiple sclerosis.
Marsh-Wakefield F; Juillard P; Ashhurst TM; Juillard A; Shinko D; Putri GH; Read MN; McGuire HM; Byrne SN; Hawke S; Grau GE
Immunol Cell Biol; 2022 Jul; 100(6):453-467. PubMed ID: 35416319
[TBL] [Abstract][Full Text] [Related]
2. Transcriptome alterations in peripheral blood B cells of patients with multiple sclerosis receiving immune reconstitution therapy.
Hecker M; Fitzner B; Boxberger N; Putscher E; Engelmann R; Bergmann W; Müller M; Ludwig-Portugall I; Schwartz M; Meister S; Dudesek A; Winkelmann A; Koczan D; Zettl UK
J Neuroinflammation; 2023 Aug; 20(1):181. PubMed ID: 37533036
[TBL] [Abstract][Full Text] [Related]
3. Restoration of regulatory B cell deficiency following alemtuzumab therapy in patients with relapsing multiple sclerosis.
Kim Y; Kim G; Shin HJ; Hyun JW; Kim SH; Lee E; Kim HJ
J Neuroinflammation; 2018 Oct; 15(1):300. PubMed ID: 30373595
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients.
Wang L; Qi CH; Zhong R; Yuan C; Zhong QY
Medicine (Baltimore); 2018 Feb; 97(8):e9908. PubMed ID: 29465579
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab for multiple sclerosis.
Riera R; Porfírio GJ; Torloni MR
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD011203. PubMed ID: 27082500
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
7. Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
Gilmore W; Lund BT; Li P; Levy AM; Kelland EE; Akbari O; Groshen S; Cen SY; Pelletier D; Weiner LP; Javed A; Dunn JE; Traboulsee AL
J Neuroinflammation; 2020 Jun; 17(1):189. PubMed ID: 32539719
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis.
Dashputre AA; Kamal KM; Pawar G
J Manag Care Spec Pharm; 2017 Jun; 23(6):666-676. PubMed ID: 28530523
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab for multiple sclerosis.
Riera R; Torloni MR; Martimbianco ALC; Pacheco RL
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD011203. PubMed ID: 37272540
[TBL] [Abstract][Full Text] [Related]
10. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
Huhn K; Bayas A; Doerck S; Frank B; Gerbershagen K; Hellwig K; Kallmann B; Kleinschnitz C; Kleiter I; Lee DH; Limmroth V; Mäurer M; Meuth S; Rieckmann P; Ruck T; Gold R; Linker RA
J Neurol; 2018 Jul; 265(7):1521-1527. PubMed ID: 29696498
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison.
Taheri S; Sahraian MA; Yousefi N
J Med Econ; 2019 Jan; 22(1):71-84. PubMed ID: 30380350
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
Van Wijmeersch B; Singer BA; Boster A; Broadley S; Fernández Ó; Freedman MS; Izquierdo G; Lycke J; Pozzilli C; Sharrack B; Steingo B; Wiendl H; Wray S; Ziemssen T; Chung L; Margolin DH; Thangavelu K; Vermersch P
Mult Scler; 2020 Nov; 26(13):1719-1728. PubMed ID: 31675266
[TBL] [Abstract][Full Text] [Related]
14. Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility.
Montgomery SM; Kusel J; Nicholas R; Adlard N
J Med Econ; 2017 Sep; 20(9):962-973. PubMed ID: 28635362
[TBL] [Abstract][Full Text] [Related]
15. CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis.
Baker D; MacDougall A; Kang AS; Schmierer K; Giovannoni G; Dobson R
Mult Scler Relat Disord; 2022 Jan; 57():103448. PubMed ID: 34902760
[TBL] [Abstract][Full Text] [Related]
16. Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.
Kocsik AS; Klein DE; Liedke M; Kaunzner UW; Nealon NM; Gauthier SA; Vartanian T; Perumal JS
J Neurol; 2018 May; 265(5):1226-1229. PubMed ID: 29666985
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Stability of Neuroaxonal Structure in Alemtuzumab-Treated Relapsing-Remitting Multiple Sclerosis Patients.
Chan JK; Hernandez Martínez de Lapiscina E; Taylor C; Nguyen AL; Alba-Arbalat S; Devonshire V; Sayao AL; Carruthers R; Costello F; Traboulsee A
J Neuroophthalmol; 2020 Mar; 40(1):37-43. PubMed ID: 32045393
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF.
Möhn N; Pfeuffer S; Ruck T; Gross CC; Skripuletz T; Klotz L; Wiendl H; Stangel M; Meuth SG
Neurol Neuroimmunol Neuroinflamm; 2020 Mar; 7(2):. PubMed ID: 31826986
[TBL] [Abstract][Full Text] [Related]
19. Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis.
Kashani N; Kelland EE; Vajdi B; Anderson LM; Gilmore W; Lund BT
Front Immunol; 2021; 12():706278. PubMed ID: 34777337
[TBL] [Abstract][Full Text] [Related]
20. Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA.
Araujo L; Kyatham S; Bzdek KG; Higuchi K; Greene N
J Comp Eff Res; 2023 Jan; 12(1):e220127. PubMed ID: 36440609
[No Abstract] [Full Text] [Related]
[Next] [New Search]